Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Tesla, Inc. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Tesla, Inc. trades at $396.5 (market cap $1.49T). The key difference: Tesla, Inc. is far larger — about 185.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap. Which is the better fit depends on your goals.
| BIO | TSLA | |
|---|---|---|
Market Cap | $8.04B | $1.49T |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $489.88 |
52-Week Low | $241.71 | $302.63 |
Enterprise Value | $7.85B | $1.46T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Tesla (TSLA) trades at $394.76, down 3.18% today amid a bearish technical signal. The stock faces pressure from elevated valuations with a P/E of 362.17 and P/S of 14.25, while recent earnings show mixed results with a Q1 2026 beat but a Q3 2025 miss. Cash flow remains positive at $579M in 2025, though net income margins have compressed to 3.95% from prior years. News highlights focus on autonomous driving approvals in Europe and a potential cheaper EV model.
The outlook is cautious; while analyst consensus is a Buy with a $409.26 target, risks include intense EV competition, execution on AI/robotics bets, and high valuation multiples. Near-term performance hinges on Q2 2026 earnings and delivery growth, with support at $391 and resistance at $399.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
